Literature DB >> 20093378

In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.

Takanori Tomozawa1, Chika Sugihara1, Masayo Kakuta1, Kiyoshi Sugihara1, Tetsufumi Koga1.   

Abstract

The postantibiotic effect (PAE) of tomopenem was determined after a 2 h exposure of two strains of meticillin-susceptible and meticillin-resistant Staphylococcus aureus (MSSA and MRSA), and imipenem-susceptible and imipenem-resistant Pseudomonas aeruginosa, to tenfold the respective MIC. The PAEs on MSSA and P. aeruginosa were approximately 1 h and they were comparable to those of meropenem. The PAE on MRSA was 1.5 to 3 h, equal to or longer than those of vancomycin. The PAEs of tomopenem not only were found for MRSA, but also were present in the imipenem-resistant P. aeruginosa tested.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20093378     DOI： 10.1099/jmm.0.017905-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN： 0022-2615            Impact factor:   2.472


  3 in total

1.  In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Kiyoshi Sugihara; Chika Sugihara; Yoko Matsushita; Naotoshi Yamamura; Mitsutoshi Uemori; Akane Tokumitsu; Harumi Inoue; Masayo Kakuta; Eiko Namba; Hatsumi Nasu; Tetsufumi Koga
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

3.  Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.

Authors:  Kiyoshi Sugihara; Kazuhiro Tateda; Naotoshi Yamamura; Tetsufumi Koga; Chika Sugihara; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.